Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of “Moderate Buy” by Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $15.00.

EPRX has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright lowered their price objective on shares of Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Zacks Research cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, William Blair assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They set an “outperform” rating on the stock.

Eupraxia Pharmaceuticals Stock Down 1.6%

EPRX opened at $6.61 on Tuesday. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $9.32. The business has a fifty day simple moving average of $8.06 and a 200-day simple moving average of $6.98. The firm has a market cap of $237.70 million, a P/E ratio of -6.42 and a beta of 1.27.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.21). Sell-side analysts expect that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Guardian Wealth Advisors LLC NC purchased a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at $76,000. Aptus Capital Advisors LLC acquired a new position in Eupraxia Pharmaceuticals during the 4th quarter worth $76,000. Bank of America Corp DE increased its holdings in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares during the period. Quadrature Capital Ltd acquired a new stake in Eupraxia Pharmaceuticals in the 2nd quarter valued at about $61,000. Finally, TCI Wealth Advisors Inc. acquired a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $65,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.